4
Changes in Ownership
Cullinan Therapeutics, Inc. Filed Acc 0000950170-24-007032
Chief Business Officer sold 40,000 shares at an average $12.31 ($492,508)
- Chief Business Officer acquired 35,875 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Savill Corrine Chief Business Officer | 2024-01-22 | Option exercise 10b5-1 | +14,559 | $4.30 | $62,604 | 184,674 | D: show line 1 in the form |
| Savill Corrine Chief Business Officer | 2024-01-22 | Sale 10b5-1 | −14,559 | $12.18 | $177,329 | 170,115 | D: show line 2 in the form |
| Savill Corrine Chief Business Officer | 2024-01-22 | Sale 10b5-1 | −4,125 | $12.02 | $49,583 | 165,990 | D: show line 3 in the form |
| Savill Corrine Chief Business Officer | 2024-01-23 | Option exercise 10b5-1 | +21,316 | $4.30 | $91,659 | 187,306 | D: show line 4 in the form |
| Savill Corrine Chief Business Officer | 2024-01-23 | Sale 10b5-1 | −21,316 | $12.46 | $265,597 | 165,990 | D: show line 5 in the form |
| Open-market sales · 40,000 sh · avg $12.31 · $492,508 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Savill Corrine Chief Business Officer | 2024-01-22 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −14,559 | 35,313 | D: show line 6 in the form | |||||
| Savill Corrine Chief Business Officer | 2024-01-23 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −21,316 | 13,997 | D: show line 7 in the form |
Loading xslF345X05/ownership.xml…